A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)

Trial Profile

A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE 173
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Jun 2017 Preliminary results (n=20) from cohorts A and B of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 29 Dec 2016 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
    • 29 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top